Evaxion Reports 75% Objective Response Rate in Phase 2 Trial for AI-Designed Cancer Vaccine

Evaxion A/S announced a 75% Objective Response Rate (ORR) in its Phase 2 trial for the AI-designed personalized cancer vaccine EVX-01. The trial involved 16 advanced melanoma patients, with 12 showing objective clinical responses, including 11 continuing to respond at 24 months follow-up. The vaccine, developed using Evaxion’s AI-Immunology™ platform, demonstrated immune activation in all patients, with 81% of targeted neoantigens triggering specific responses. The treatment was well-tolerated, and data was presented at the ESMO Congress 2025. Evaxion plans to discuss the results with stakeholders and potential partners, with further clinical development expected to be conducted in partnership.